Patients all over the world should benefit from the achievements of predictive medicine and the introduction of in silico trials, which promise the accelerated and safe introduction of new products such as medical devices or pharmaceuticals to the market place. These concepts cannot be developed by academics or in industry alone, and ultimately they need to be accepted by regulatory agencies around the world. When regulators accept simulation augmented submissions, and agree upon a common model credibility assessment philosophy will patients benefit from the utilization of in silico medicine.

The objective of the Avicenna Alliance International Working Group is the promotion of the benefits of predictive medicine and in silico trials through the global connections of experts from academia, industry, and regulatory agencies. Together we will work on developing objective standards, increasing confidence in in silico methods and their acceptance in support of regulatory approval process.

 

The key goals of this group are:

  • Continue facilitating dialogue on in silico with regulators and actors around the world and seek opportunities to expand the Alliance geographically by actively engaging with priority countries, and following-up with additional countries.
  • Reach global convergence and harmonization on the regulation/ guidance for the use of in silico as evidence.

 

Priorities in 2019 and 2020

→ Identification of strategic contacts and implementation of an outreach plan;
→ Participation in international events to represent the Avicenna Alliance;
→ Planification and organisation of local events;
→ Contribution to the upcoming Avicenna Alliance White Papers.

Working group leader:

  • Markus Reiterer
  • Distinguished Scientist, Technical Fellow, Medtronic, PLC (Minneapolis, USA)

Avicenna Alliance news

Quantum technologies are getting momentum in the EU

On February 27 Austria, Bulgaria, Denmark and Romania have agreed to work together with 20 other EU Member States towards the development of a...

find out more ›

The Avicenna Alliance answers the consultation for Europe’s Beating Cancer Plan

On 3 March 2020, the Avicenna Alliance has submitted feedback on the roadmap of Europe’s Beating Cancer Plan. With...

find out more ›

European Commission's Data Strategy mentions benefits of CM&S and digital twins

On 19 February, the European Commission has released a communication addressing the European strategy for data which...

find out more ›

Show all activites

Sign up for our monthly newsletter!


Sign up